Testing blood thinners in adults with inherited bleeding vessel disease
Part of Blood & lymphatic, Ear, nose & throat, Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study looks at people with Rendu-Osler (hereditary hemorrhagic telangiectasia) who have just started blood-thinning medicines. It aims to understand how antiplatelet and/or anticoagulant therapy affects safety and outcomes soon after starting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (over 18 years old)
- Have Rendu-Osler disease (hereditary hemorrhagic telangiectasia)
- You just started (less than 3 months ago) an antiplatelet and/or anticoagulant medicine for a medical reason
- You can understand the study and agree to participate
- Be enrolled in a social security system
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called DIAG723 in adults with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and bleeding. Depending on which part of the study you qualify for, the drug may help reduce nosebleeds, improve anemia, or help with lung blood vessel problems caused by HHT.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
This study looks at pregnancy and the early period after birth in women with rare diseases that affect blood vessels. It may help doctors understand risks and improve care for future pregnancies.
This trial tests a new drug called ATV-1601 in people with HHT, a genetic condition that causes abnormal bleeding and blood vessel problems. The drug aims to reduce bleeding and anemia caused by HHT.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
Hear when a new Hereditary Hemorrhagic Telangiectasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.